A diagnosis before the operating theatre.
DatChem-Ovary reads the chemistry of ovarian tissue directly, distinguishing a benign mass from a malignant one before any incision is made.
That pre-operative certainty changes the conversation, informing whether surgery is needed at all, and how extensive it should be, without first resorting to a biopsy.
- Benign vs malignant. Reads tissue chemistry to tell one from the other.
- Pre-operative diagnosis. A clear answer ahead of surgery, with no biopsy.
- Considered surgery. Supports better planning and helps avoid unnecessary operations.
What earlier certainty makes possible.
Non-invasive
An answer from tissue chemistry, with no biopsy and nothing taken before surgery.
Pre-operative certainty
Benign or malignant is known ahead of time, not confirmed after the operation.
Better surgical planning
Informs the need for, and the extent of, surgery, and helps avoid unnecessary operations.
From scan to report, on existing scanners.
DatChem-Ovary adds a short sequence to a standard MRI, no new hardware, with results returned to the physician in minutes.
Patient scan
A short scan in a standard MRI captures the raw spectral data, no contrast, no biopsy.
Data capture
Raw data is transmitted securely from the scanner to the DatChem cloud, region by region.
Data processing
The chemical signature is extracted and compared against our exclusive databases.
Physician report
A report informs whether the tumour is benign or malignant, ahead of any surgery.
DatChem's technologies are undergoing regulatory evaluation (TGA, FDA and EMA) and are not yet approved for routine clinical use in all markets.
Bring DatChem-Ovary to your centre.
For clinical, research or partnership enquiries about DatChem-Ovary, we'd be glad to hear from you.